{
 "source": "Assay Systems register, https://assay-systems.com/register/",
 "key_tier": "none",
 "data": {
  "url": "https://assay-systems.com/register/ca/grants/r/qu-biologics-inc/",
  "assay_record": "ASY-CA-0SGPKTM1DL",
  "summary": "14 federal grant and contribution agreements worth $9.2M with Qu Biologics Inc., 2009–2024.",
  "name": "Qu Biologics Inc.: federal grants and contributions",
  "register": "",
  "dates": [],
  "tiles": [],
  "sections": [],
  "figures": [
   {
    "value": "14",
    "label": "agreements"
   },
   {
    "value": "$9.2M",
    "label": "value"
   },
   {
    "value": "1",
    "label": "departments"
   },
   {
    "value": "3",
    "label": "programs"
   }
  ],
  "text": [
   "This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immunity and/or reduction of morbidity and mortality from COVID-19 in a test population of adults 65 years of age or older in long term care or assisted living facilities.",
   "This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.",
   "This project aims to generate preclinical data showing that solid tumours can be better accessed and targeted by CAR T cells when the Firm's proprietary platform immunotherapy, Site-Specific Immunomodulators (SSIs), are used in conjunction as neoadjuvant therapy.",
   "The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.",
   "The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.",
   "Develop processes and methods for quality control analytics and aseptic reagent and product handling, in preparation for commercial scale lot production of QBKPN, the Firm's lung-specific Site Specific Immunomodulator (SSI), for use in a planned clinical trial for COVID-19 prevention.",
   "The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.",
   "The Project will support development of intellectual property capacity within the Firm."
  ],
  "records": [
   {
    "name": "grants and contributions register",
    "url": "https://assay-systems.com/register/ca/grants/"
   },
   {
    "name": "Burnaby North–Seymour",
    "url": "https://assay-systems.com/register/ca/grants/riding/59003-burnaby-north-seymour/"
   },
   {
    "name": "National Research Council Canada",
    "url": "https://assay-systems.com/register/ca/grants/department/national-research-council-canada/"
   }
  ],
  "cite_as": "Assay Systems, \"Qu Biologics Inc.: federal grants and contributions\", https://assay-systems.com/register/ca/grants/r/qu-biologics-inc/"
 }
}